Deloitte January 10, 2019
As the health care world continues its shift from volume- to value-based reimbursement, value-based contracts (VBC) between life sciences companies and payers that tie the reimbursement of a product to the value it delivers are gaining traction.
The health care system is going through a volume-to-value transformation with the goal of controlling cost and improving patient outcomes. At the same time, we are seeing tremendous innovation in new therapies that are being developed to help dramatically improve patient outcomes. The health care system is challenged with how to provide sufficient access to these new therapies while controlling overall health care spending.
Pressure to demonstrate value is increasingly intense on life sciences companies as more personalized therapies come to market....